MyCartis
An immuno-diagnostic solution provider assuring accurate, clinical guidance with its sample to answer Evalution platform.
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | - | - | - |
| % growth | (90 %) | 200 % | 3883 % | (51 %) | - | - | - |
| EBITDA | (6.6m) | (8.8m) | (6.3m) | 1.5m | (<1m) | - | - |
| % EBITDA margin | (331100 %) | (146067 %) | (2623 %) | 1313 % | - | - | - |
| Profit | (6.9m) | (9.2m) | (6.8m) | <1m | (<1m) | <1m | <1m |
| % profit margin | (346200 %) | (152733 %) | (2851 %) | 140 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
| Total Funding | - | ||
Recent News about MyCartis
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.